Silence Therapeutics (Silence Therapeutics) Total Assets : $118.76 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics Total Assets?

Silence Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $118.76 Mil.

During the past 12 months, Silence Therapeutics's average Total Assets Growth Rate was 13.70% per year. During the past 3 years, the average Total Assets Growth Rate was -8.30% per year. During the past 5 years, the average Total Assets Growth Rate was 25.90% per year. During the past 10 years, the average Total Assets Growth Rate was 15.70% per year.

During the past 13 years, Silence Therapeutics's highest 3-Year average Total Assets Growth Rate was 159.40%. The lowest was -44.50%. And the median was 18.25%.

Total Assets is connected with ROA %. Silence Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -60.82%. Total Assets is also linked to Revenue through Asset Turnover. Silence Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.02.

Silence Therapeutics Total Assets Historical Data

The historical data trend for Silence Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Total Assets Chart

Silence Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

60.39

115.55

127.92

130.94

118.76

Silence Therapeutics Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Assets	Get a 7-Day Free Trial															130.94	114.49	117.06	121.22	118.76

Silence Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Silence Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	21.582	+	97.18
	=	118.76

Silence Therapeutics's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	21.582	+	97.18
	=	118.76

Silence Therapeutics (NAS:SLN) Total Assets Explanation

Total Assets is connected with ROA %.

Silence Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-72.972	/	( (121.215	+	118.762)	/ 2 )
	=	-72.972	/	119.9885
	=	-60.82 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Silence Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	2.657	/	( (121.215	+	118.762)	/ 2 )
=	2.657	/	119.9885
=	0.02

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Silence Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Silence Therapeutics (Silence Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (NAS:SLN) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

SLNCF:USA XRP2:Germany

Address

72 Hammersmith Road, London, GBR, W14 8TH

Website

https://www.silence-therapeutics.com

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.